Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects, introducing a delay. Similarly, poorly soluble (lipophilic) drugs may exhibit gradual absorption due to slow dissolution in the gastrointestinal (GI) tract, thereby delaying onset times.
In contrast, modified-release (MR) dosage forms have been developed to achieve specific therapeutic goals and enhance patient adherence. These formulations deliberately alter the drug's release rate and timing, providing a more effective alternative to conventional IR forms. By controlling the release of the therapeutic agent, MR formulations ensure consistent drug absorption from the GI tract. Common types of MR oral drug products include extended-release, delayed-release, targeted-release, and orally disintegrating tablets.
Extended-release (ER) formulations are engineered to release the drug gradually over an extended period, significantly reducing dosing frequency compared to IR forms. These formulations utilize advanced technologies such as matrix systems, which control the release of the drug by embedding it in a matrix that dissolves over time, and osmotic pumps, which release the drug through a small opening in a semipermeable membrane, to maintain steady drug levels in the bloodstream. This minimizes fluctuations and improves patient adherence. Delayed-release (DR) formulations release the drug at a specific time after ingestion, often employing enteric coatings to resist stomach acid and ensuring release in the intestines for optimal absorption and reduced gastric irritation. This approach is exemplified by enteric-coated aspirin, which enhances therapeutic efficacy while mitigating side effects.
Targeted-release formulations deliver drugs directly to specific physiological sites, enhancing therapeutic effects and minimizing systemic exposure. This is achieved through advanced drug carrier systems like liposomes or nanoparticles, which enable precise delivery and localized action, which are beneficial in treatments like cancer therapy. Orally disintegrating tablets (ODTs) dissolve rapidly in saliva, facilitating quick drug absorption without water, making them particularly suitable for patients with swallowing difficulties.
Overall, MR drug products are meticulously designed based on the drug's physicochemical properties and the characteristics of the formulation materials.
Conventional immediate-release formulations release the active ingredient immediately upon ingestion, leading to rapid absorption. However, formulations containing poorly soluble drugs may exhibit slower absorption.
To overcome these limitations, modified-release dosage forms have been designed to control drug release patterns. Several types of modified-release oral drug products are available.
Extended-release formulations are designed to sustain drug release, maintain therapeutic levels over longer durations, and reduce dosing frequency.
Delayed-release formulations, often with enteric coatings, protect the drug from the acidic stomach environment and ensure drug release only in the intestines, optimizing absorption profiles.
Targeted-release formulations deliver drugs to specific body sites, maximizing therapeutic effects and minimizing systemic exposure. These formulations can be designed for either immediate or sustained drug release.
Orally disintegrating tablets dissolve rapidly in saliva, enabling direct buccal drug absorption and quicker therapeutic effects. They are ideal for patients who have difficulty swallowing conventional tablets.
繁體中文
